Aprea Therapeutics (APRE) announced that the first patient has been dosed at Dose Level 7, evaluating ATRN-119 550 mg twice daily, in the ongoing ABOYA-119 Phase 1/2a clinical trial. The ABOYA-119 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback